Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

GLAUKOS CORPORATION

(GKOS)
  Report
Delayed Nyse  -  04:00:01 2023-01-27 pm EST
48.04 USD   -0.29%
01/11Glaukos Announces Positive Results for iDose TR Exchange Trial Highlighting Favorable Safety and Tolerability
AQ
01/10Transcript : Glaukos Corporation Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-10-2023 05:15 PM
CI
01/10Glaukos Says iDose TR Exchange Trial Shows 'Favorable' Safety, Tolerability; Shares Up After Hours
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about GLAUKOS CORPORATION
01/11Glaukos Announces Positive Results for iDose TR Exchange Trial Highlighting Favorable S..
AQ
01/10Transcript : Glaukos Corporation Presents at 41st Annual J.P. Morgan Healthca..
CI
01/10Glaukos Says iDose TR Exchange Trial Shows 'Favorable' Safety, Tolerability; Shares Up ..
MT
01/10Glaukos : Investor Presentation January 2023
PU
01/10Glaukos Corp : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
01/10Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Program..
BU
01/10Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable ..
BU
01/10Glaukos Corporation Announces Positive Results for iDose TR Exchange Trial, Highlightin..
CI
01/10Glaukos Corporation Announces Positive Clinical Updates for Several Corneal Health Pipe..
CI
2022Glaukos Announces Participation in the J.P. Morgan Healthcare Conference 2023
AQ
2022Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
BU
2022Stephens Trims Price Target on Glaukos to $68 From $69, Maintains Overweight Rating
MT
2022Mizuho Initiates Glaukos With Neutral Rating, Price Target is $48
MT
2022Glaukos Corp : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial ..
AQ
2022North American Morning Briefing: Futures Waver -2-
DJ
2022JPMorgan Upgrades Glaukos to Neutral From Underweight, Adjusts Price Target to $42 From..
MT
2022North American Morning Briefing: Crucial -3-
DJ
2022Wells Fargo Adjusts Price Target on Glaukos to $44 From $56, Maintains Equal-Weight Rat..
MT
2022Citigroup Upgrades Glaukos to Buy From Neutral, Keeps Price Target at $57
MT
2022Glaukos : Investor Presentation November 2022
PU
2022Glaukos Corp : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
2022Glaukos Announces Participation in the Stephens Annual Investment Conference
BU
2022GLAUKOS CORP Management's Discussion and Analysis of Financial Condition and Results o..
AQ
2022Needham Adjusts Price Target on Glaukos to $65 From $66, Maintains Buy Rating
MT
2022Piper Sandler Adjusts Glaukos' Price Target to $60 From $55, Keeps Neutral Rating
MT
2022Glaukos : Q3 Earnings Snapshot
AQ
2022Transcript : Glaukos Corporation, Q3 2022 Earnings Call, Nov 02, 2022
CI
2022Earnings Flash (GKOS) GLAUKOS CORPORATION Posts Q3 Revenue $71.3M
MT
2022Earnings Flash (GKOS) GLAUKOS CORPORATION Posts Q3 Loss $-0.45
MT
2022Glaukos Corp : Results of Operations and Financial Condition, Regulation FD Disclosure, Fi..
AQ
2022Glaukos Corporation Announces Third Quarter 2022 Financial Results
BU
2022Glaukos Corporation Revises Revenue Guidance for the Year 2022
CI
2022Glaukos Corporation Reports Earnings Results for the Third Quarter and Nine Months Ende..
CI
2022Stephens Reinstates Glaukos at Overweight With $69 Price Target
MT
2022Glaukos to Release Third Quarter 2022 Financial Results after Market Close on November ..
BU
2022Needham Starts Glaukos at Buy With $66 Price Target, Citing Potential to Regain Market ..
MT
2022Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Aca..
BU
2022Coupa Software, Glaukos rise; Occidental Petroleum falls
AQ
2022Sector Update: Health Care Stocks Gaining Steam in Late Trade
MT
2022Sector Update: Health Care Stocks Rebounding Wednesday After Long Retreat
MT
2022Top Midday Gainers
MT
2022Glaukos Says Results of Phase 3 Trials of iDose TR Met Primary Efficacy Endpoints, Plan..
MT
2022Sector Update: Health Care Stocks Mixed Premarket Wednesday
MT
2022Glaukos Says Results of Phase 3 Trials of iDose TR Met Primary Efficacy Endpoints, Plan..
MT
2022Glaukos Corp : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
2022Glaukos Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR..
BU
2022Glaukos Corporation Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials..
CI
2022Glaukos Reports 1 Million Uses of iStent Products
MT
2022Glaukos Announces More Than 1 Million iStent« Technologies Implanted Worldwide
BU
2022Burns & Levinson Represents iVeena Delivery Systems, Inc. in Strategic Licensing Agreem..
PR
2022Sector Update: Health Care Stocks Inching Higher Near Close
MT
2022Sector Update: Health Care Stocks Left Grappling for Direction in Uncertai..
MT
2022Glaukos Announces Participation in the Wells Fargo Healthcare Conference
BU
2022Glaukos Secures License to Investigational Corneal Disorder Treatment
MT
2022Glaukos Licenses Iveena’S Investigational Keratoconus Therapy
CI
2022Insider Sell: Glaukos
MT
2022GLAUKOS CORP Management's Discussion and Analysis of Financial Condition and Results o..
AQ
2022Glaukos : Q2 Earnings Snapshot
AQ
2022Glaukos : Announces Second Quarter 2022 Financial Results - Form 8-K
PU
2022Transcript : Glaukos Corporation, Q2 2022 Earnings Call, Aug 03, 2022
CI
2022Glaukos Corp : Results of Operations and Financial Condition, Regulation FD Disclosure, Fi..
AQ
2022Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q2 Revenue $72.7M
MT
2022Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q2 Loss $-1.21
MT
2022Glaukos Corporation Announces Second Quarter 2022 Financial Results
BU
2022Glaukos Announces FDA 510(k) Clearance of iStent infinite«
BU
2022Glaukos Corporation Announces FDA 510(k) Clearance of iStent Infinite
CI
2022Glaukos Corporation Reports Earnings Results for the Second Quarter and Six Months Ende..
CI
2022Glaukos Corporation Revises Sales Guidance for the Year 2022
CI
2022Glaukos Corporation Reports Earnings Results for the Second Quarter and Six Months Ende..
CI
2022Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3
BU
2022Sector Update: Health Care Stocks Drop on Tuesday
MT
2022Glaukos Shares Rise After Stifel Upgrade
MT
2022Sector Update: Health Care Stocks Drifting Lower This Afternoon
MT
2022Stifel Upgrades Glaukos to Buy From Hold, Adjusts Price Target to $60 From $40
MT
2022Glaukos Corp : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
1  2  3  4  5  6  7  8Next
Upcoming event on GLAUKOS CORPORATION